14C-Labelled compound TR-2, a tremorgenic mycotoxin, was administered to Penicillium raistrickii in submerged fermentation. Half of the added radiolabel was taken up by the fungus during the 60 h incubation period and the secondary metabolites subsequently isolated, principally verruculogen but also fumitremorgin B, were found to be radiolabelled. The efficiency of biosynthetic incorporation of TR-2 into verruculogen within the mycelium was at least 35%, demonstrating for the first time an intermediary role for TR-2. Fumitremorgin B was also TR-2-derived but may not be an important intermediate in verruculogen biosynthesis.
A strain of Clauiceps purpurea, which has consistently failed to elaborate ergot alkaloids when growing as a parasite, has been shown to perform only the first step of the ergoline biosynthetic pathway catalysed by dimethylallyltryptophan (DMAT) synthetase. The next step, involving Nmethylation of DMAT, did not operate.[ 14C]Agroclavine and lysergic acid, normally intermediates in alkaloid biosynthesis, were accepted by parasitic sclerotial tissue as substrates and were metabolized to lysergic acid amide (LAA). This amide therefore constituted a previously unreported end product for C. purpurea. It is concluded that the mutant has a metabolic block in the pathway following DMAT and, while enzymes for several subsequent steps are present, the fungus seems unable to form the usual cyclic tripeptide ergot alkaloids. The steps involved in metabolizing agroclavine to LAA were insensitive to 1 M-phosphate, while this concentration of phosphate completely inhibited DMAT synthetase. This double mutant therefore has unique potential for exploring control mechanisms in ergot alkaloid biosynthesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.